ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2017

Aug 11, 2017

SEC Form 4/A — Form 4/A

Issuer: ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK: 0000949858
Period of Report: 2017-08-01

Reporting Person: Stewart Richard Alistair (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-01	Common Stock	A	1950309	—	Acquired	1950309	Direct
2017-08-01	Common Stock	A	71861	—	Acquired	71861	Indirect
2017-08-01	Common Stock	A	176418	—	Acquired	176418	Indirect

Footnotes

F1: This amended Form 4 is filed to correct the number of common shares received in exchange for 5,428 common shares of Achieve Life Science, Inc. ("Achieve") pursuant to the merger between OncoGenex Pharmaceuticals, Inc. ("OncoGenex") and Achieve (the "Merger"). On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect an 11-for-1 reverse stock split effected on August 1, 2017 (the "Reverse Stock Split").

F2: This amended Form 4 is filed to correct the number of common shares received in exchange for 200 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split.

F3: This amended Form 4 is filed to include the number of common shares received in exchange for 491 common shares of Achieve pursuant to the Merger. On the effective date of the Merger, the closing price of Achieve's common stock was $4.576 per share, representing a closing price of $0.416 per share of OncoGenex's common stock as adjusted to reflect the Reverse Stock Split.

F4: The reporting holder is a principal owner of Ricanto Limited.